100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Patent number: 8568730Abstract: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.Type: GrantFiled: April 22, 2010Date of Patent: October 29, 2013Assignee: Indiana University Research & Technology CorporationInventor: David S. Wilkes
-
Publication number: 20130280262Abstract: The present invention provides polypeptides and compositions thereof for treating or limiting respiratory syncytial virus infection, and computational methods for designing such polypeptides.Type: ApplicationFiled: October 6, 2011Publication date: October 24, 2013Applicant: University of Washington Through Its Center For CommercializationInventors: William R. Schief, Bruno E. Correia, David Baker
-
Publication number: 20130281356Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
-
Patent number: 8563504Abstract: The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and their use for the treatment and control of infections caused by gram-positive bacteria, including Staphylococcus aureus.Type: GrantFiled: October 9, 2009Date of Patent: October 22, 2013Assignee: Lusomedicamenta, S.A.Inventors: Miguel Ângelo da Costa Garcia, Madalena Maria Vilela Pimentel, Carlos Jorge Sousa de São José
-
Patent number: 8563521Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which are Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: GrantFiled: June 20, 2008Date of Patent: October 22, 2013Assignee: Technische Universitat MunchenInventors: Arne Skerra, Ina Theobald, Martin Schlapschy
-
Patent number: 8563513Abstract: Provided herein are Parathyroid hormone (PTH) peptides and parathyroid hormone-related protein (PTHrP) peptides (e.g., PTH analogs, PTHrP analogs), and related variants, chemical derivatives, fusion polypeptides, multimeric polypeptides, and peptidomimetics, peptoids, the like. Also provided are their use in methods for activating the PTH receptor in a cell (e.g., an osteoblast), methods of treating a subject with bone loss (e.g., by administration of a PTH peptide or PTHrP peptide (e.g., a PTH analog or PTHrP analog)), methods of ameliorating a symptom associated with osteoporosis in a subject, methods of retarding the progression of osteoporosis in a subject, and methods of regenerating bone in a subject.Type: GrantFiled: March 26, 2010Date of Patent: October 22, 2013Assignees: Van Andel Research Institute, The General Hospital CorporationInventors: Huaqiang Eric Xu, Augen A. Pioszak, Thomas J. Gardella
-
Patent number: 8557774Abstract: Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof.Type: GrantFiled: September 22, 2009Date of Patent: October 15, 2013Assignee: Centre Hospitalier Universitaire deInventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
-
Patent number: 8552159Abstract: Provided herein are carbohydrate complement-modified bifunctional glycoproteins, and their use in tumor-selective therapy. The bifunctional glycoproteins comprise a first component that specifically binds to a tumor-specific antigen and a second component having enzymatic activity by means of which a non-toxic prodrug is cleaved into a cytotoxic drug. The carbohydrate complement comprises at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, N-acetyllactose, glucose and fucose. The modified carbohydrate complement contributes to increased relative concentration of the glycoproteins at the site of the tumor, and enhanced clearance from the general circulation and non-tumor sites.Type: GrantFiled: April 2, 2004Date of Patent: October 8, 2013Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Joerg Czech, Dieter Hoffmann
-
Publication number: 20130261053Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicants: ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130251713Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: ROBERT COHEN, SUZETTE BELDER-CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
-
Publication number: 20130251712Abstract: The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind.Type: ApplicationFiled: November 28, 2011Publication date: September 26, 2013Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Maureen D. O'Connor-McCourt, Traian Sulea, Catherine Collins, Myriam Banville, Maria L. Jaramillo
-
Patent number: 8541236Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.Type: GrantFiled: December 6, 2007Date of Patent: September 24, 2013Assignees: University of Washington, The Children's Hospital & Research Center At OaklandInventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
-
Patent number: 8541376Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.Type: GrantFiled: May 28, 2008Date of Patent: September 24, 2013Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
-
Patent number: 8541373Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.Type: GrantFiled: December 7, 2010Date of Patent: September 24, 2013Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Liora Sklair-Tavron, Moti Rosenstock, Liron Shemesh-Darvish, Hussein Hallak, Victor Piryatinsky, Viktor Roschke, David Lafleur
-
Patent number: 8540977Abstract: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.Type: GrantFiled: July 25, 2011Date of Patent: September 24, 2013Assignee: CSL LimitedInventor: Manuel Baca
-
Patent number: 8541378Abstract: The present invention relates to recombinant albumins fused with poly-cysteine peptide and methods for preparing the same, more precisely recombinant albumins in which cysteines that can be used for drug binding are amplified at N-terminal and C-terminal of the albumin and methods for preparing the same. The recombinant albumin of the present invention demonstrates improved albumin-drug conjugation efficiency when it is used for drug delivery system, indicating that it can effectively deliver a large amount of drug to a target tissue. At the same time, the recombinant albumin of the present invention can be used as an excellent drug deliverer with reduced side effects, compared with the conventional albumin carriers, by regulating the amount of drug conjugated to each unit of albumin by regulating the number of cysteine fused thereto.Type: GrantFiled: June 2, 2010Date of Patent: September 24, 2013Assignee: Korea Institute of Science and TechnologyInventors: Hyung Jun Ahn, Ick Chan Kwon, Kuiwon Choi, Kwangmyeng Kim, Inchan Youn, Sehoon Kim
-
Publication number: 20130243781Abstract: The invention provides cDNAs which encodes a signal peptide-containing proteins. It also provides for the use of a cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.Type: ApplicationFiled: February 8, 2013Publication date: September 19, 2013Applicant: Incyte CorporationInventors: Preeti G. LAL, Janice Au-Young, Roopa Reddy, Lynn E. Murry, Preete Mathur
-
Publication number: 20130243745Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: June 1, 2011Publication date: September 19, 2013Applicants: ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Publication number: 20130244955Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: August 16, 2011Publication date: September 19, 2013Inventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
-
Publication number: 20130243779Abstract: The present invention relates to a protective peptide of Enterococcus faecalis (E. faecalis) or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing an E. faecalis infection; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: February 4, 2010Publication date: September 19, 2013Applicant: Intercell AGInventors: Eszter Nagy, Beatrice Tschanun, Markus Hanner, Manfred Berger, Andreas Meinke, Alexander Von Gabain, Barbara Murray, Kavindra Singh
-
Publication number: 20130244954Abstract: The invention is in the field of biotechnology. Specifically it describes the application and pharmaceutical composition of Reg4. The invention describes the applications of the protein as following in (a) or (b) in preparing drugs for treating acute pancreatitis: (a) the protein whose amino acid sequence is shown as SEQ ID NO. 1, or bioactive fragments, or analogs; (b) the proteins whose amino acid sequence have at least 70% homology comparing with amino acid sequence described in (a) and have activity for treating acute pancreatitis. The protein described in this invention treats acute pancreatitis effectively and may provide new therapy for treating acute pancreatitis clinically.Type: ApplicationFiled: August 8, 2011Publication date: September 19, 2013Applicant: SHANGHAI REGENOME BIOMEDICAL TECHNOLOGY CO., LTD.Inventors: Wei Han, Yan Yu, Guoyong Hu
-
Patent number: 8536127Abstract: Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal ?-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.Type: GrantFiled: November 22, 2005Date of Patent: September 17, 2013Assignee: Novo Nordisk Healthcare AGInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt, Kirsten Kramer Jakobsen
-
Patent number: 8535941Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.Type: GrantFiled: February 27, 2012Date of Patent: September 17, 2013Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
-
Patent number: 8536128Abstract: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases.Type: GrantFiled: March 8, 2011Date of Patent: September 17, 2013Assignee: New York UniversityInventors: Chuanju Liu, Sally Frenkel
-
Patent number: 8536117Abstract: A method for the treatment of cardiovascular disease or disorder in a subject in need thereof, the method comprising the steps of administering an ApoA1 mimetic that is capable of promoting cholesterol efflux from lipid loaded cells in the subject, wherein the ApoA1 mimetic has an amino acid sequence that includes at least a portion of the amino acid sequence of ApoA1 or a mimetic of ApoA1 that contains at least one tryptophan, at least one tryptophan from the ApoA1 or mimetic of the ApoA1 being substituted with an oxidant resistant amino acid in the amino acid sequence of the ApoA1 mimetic.Type: GrantFiled: February 14, 2012Date of Patent: September 17, 2013Assignee: The Cleveland Clinic FoundationInventors: Jonathan D. Smith, Stanley L. Hazen
-
Publication number: 20130236509Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.Type: ApplicationFiled: July 14, 2011Publication date: September 12, 2013Applicant: DELTA CRYSTALLON B.V.Inventor: Johannes Maria Van Noort
-
Publication number: 20130237472Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof.Type: ApplicationFiled: September 7, 2011Publication date: September 12, 2013Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20130236440Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 3, 2011Publication date: September 12, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Patent number: 8530416Abstract: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.Type: GrantFiled: April 3, 2012Date of Patent: September 10, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Rony Seger, Galia Maik-Rachline
-
Patent number: 8530417Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.Type: GrantFiled: December 29, 2007Date of Patent: September 10, 2013Assignee: Biosteed Gene Expression Tech Co. Ltd.Inventors: Shiyuan Wang, Jianhua Zheng, Li Sun, Huili Cai, Meihua Yang, Yan He, Ping Chen, Hongyuan Deng, Liping Zhong, Shuying Huang
-
Patent number: 8530431Abstract: Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.Type: GrantFiled: March 23, 2010Date of Patent: September 10, 2013Assignee: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20130231293Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.Type: ApplicationFiled: November 21, 2012Publication date: September 5, 2013Applicant: Corixa CorporationInventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
-
Publication number: 20130230507Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 4, 2011Publication date: September 5, 2013Applicant: ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130230532Abstract: The present invention provides a novel myomegalin isoform—myomegalin variant 8 (MMG8). The myomegalin variant 8 regulates microtubule organization at the Golgi apparatus, protein modification, secretion and trafficking, and cell proliferation. The present invention also provides nucleic acid molecules encoding the myomegalin isoforms, and vectors and host cells containing the nucleic acid molecules. Also provided are fusion constructs comprising the myomegalin isoform and antibodies that bind specifically to the myomegalin isoforms of the present invention. The present invention further provides uses of the myomegalin isoform as a diagnostic biomarker and as a target for screening for therapeutics for diseases such as cancer, diabetes, and lysosomal storage diseases.Type: ApplicationFiled: November 15, 2011Publication date: September 5, 2013Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Zhe Wang, Robert Zhong QI
-
Publication number: 20130230500Abstract: The invention provides for the use of any form of botulinum toxin, or any enzymatically active derivative thereof, to cause temporary paralysis of the muscles of the lips of the mouth to promote smoking cessation.Type: ApplicationFiled: March 1, 2012Publication date: September 5, 2013Inventor: Abbas Mehdi
-
Patent number: 8524241Abstract: The invention features recombinant exotoxins from Vibrio cholerae are for the therapeutic treatment of a variety of human diseases, particularly diseases characterized by an abundance or excess of undesired cells.Type: GrantFiled: July 18, 2008Date of Patent: September 3, 2013Assignee: The General Hospital CorporationInventors: Brian Seed, Jia Liu Wolfe, Chia-Lun Tsai
-
Patent number: 8524656Abstract: A conjugate protein comprising a GM-CSF or a fragment thereof and a truncated CCL2 is described. The conjugate protein has unexpected immune suppressive, anti-obesity and tumoricidal properties and is useful in a variety of therapeutic applications.Type: GrantFiled: July 8, 2009Date of Patent: September 3, 2013Inventors: Jacques Galipeau, Moutih Rafei
-
Patent number: 8524653Abstract: Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins, and methods of identifying and making such improved polypeptides are described.Type: GrantFiled: September 22, 2009Date of Patent: September 3, 2013Assignee: Aileron Therapeutics, Inc.Inventors: Huw M. Nash, David Allen Annis, Rosana Kapeller-Llbermann, Tomi K. Sawyer, Noriyuki Kawahata
-
Patent number: 8524869Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: GrantFiled: March 22, 2010Date of Patent: September 3, 2013Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Publication number: 20130224174Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: July 12, 2011Publication date: August 29, 2013Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130225484Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: AMGENInventor: AMGEN
-
Publication number: 20130225480Abstract: The present invention relates to a method of promoting bronchodilation by administration of streptolysin O to a subject in need thereof.Type: ApplicationFiled: February 27, 2013Publication date: August 29, 2013Applicant: BEECH TREE LABS, INC.Inventor: Beech Tree Labs, Inc.
-
Publication number: 20130224146Abstract: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.Type: ApplicationFiled: February 24, 2012Publication date: August 29, 2013Inventors: Yvonne M. Chen, Anan Chuntharapai, Dimitry Danilenko, Wenjun Ouyang, Susan Sa, Patricia Valdez, Terence Wong, Jianfeng Wu, Yan Zheng
-
Patent number: 8518412Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co, Ltd.Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
-
Patent number: 8518389Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.Type: GrantFiled: December 16, 2008Date of Patent: August 27, 2013Assignee: Human Genome SciencesInventors: Steven M. Ruben, Kevin P. Baker
-
Patent number: 8518887Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: June 25, 2010Date of Patent: August 27, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Publication number: 20130217637Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: November 21, 2012Publication date: August 22, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: The Trustees of Columbia University in the City of
-
Publication number: 20130216504Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.Type: ApplicationFiled: December 21, 2012Publication date: August 22, 2013Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCEInventor: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE